CD4 and neoplasm: Hercbergs et al. reported that the clinical progress of far-advanced pancreatic cancer is slowed by withdrawal of endogenous T4 [53], and our data suggest that P-bi-TAT blocks the receptor and the uptake of T4, leading to the reduction in tumor growth.